{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Type+1+interferon&page=9", "query": { "intervention": "Type 1 interferon", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 284, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Type+1+interferon&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Type+1+interferon&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:24:05.337Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05400122", "title": "Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Hematologic Malignancy", "Rectum Cancer", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Myeloproliferative Syndrome", "Plasma Cell Myeloma", "Gastric Cancer", "Esophageal Cancer", "Esophagus Cancer", "Gastric Cancer, Metastatic", "Unresectable Esophageal Cancer", "Metastatic Esophageal Cancer" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Natural Killer Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Wald", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-09-09", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-11-15T12:24:05.337Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05400122" }, { "nct_id": "NCT02530047", "title": "Mesenchymal Stem Cells (MSC) for Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "MSC-INFβ", "type": "GENETIC" }, { "name": "Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "GENETIC", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "18 Years to 90 Years · Female only" }, "enrollment_count": 5, "start_date": "2016-05-16", "completion_date": "2019-06-13", "has_results": false, "last_update_posted_date": "2019-07-18", "last_synced_at": "2026-11-15T12:24:05.337Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02530047" }, { "nct_id": "NCT02584829", "title": "Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Merkel Cell Polyomavirus Infection", "Stage IV Merkel Cell Carcinoma AJCC v7" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Recombinant Interferon Beta", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-11-06", "completion_date": "2018-12-18", "has_results": true, "last_update_posted_date": "2022-03-22", "last_synced_at": "2026-11-15T12:24:05.337Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02584829" }, { "nct_id": "NCT00138151", "title": "Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "recombinant interferon alpha-2b", "type": "BIOLOGICAL" }, { "name": "isotretinoin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2001-03", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2013-11-20", "last_synced_at": "2026-11-15T12:24:05.337Z", "location_count": 6, "location_summary": "Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Hamilton", "state": "New Jersey" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00138151" }, { "nct_id": "NCT00002574", "title": "Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "omacetaxine mepesuccinate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 87, "start_date": "1994-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-05", "last_synced_at": "2026-11-15T12:24:05.337Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002574" }, { "nct_id": "NCT00235989", "title": "Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Interferon beta 1b (Betaseron, BAY86-5046)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 63, "start_date": "2003-06", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2014-05-08", "last_synced_at": "2026-11-15T12:24:05.337Z", "location_count": 17, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00235989" }, { "nct_id": "NCT00445523", "title": "Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "TroVax® (Immunological Vaccine Therapy)", "type": "BIOLOGICAL" }, { "name": "Interferon-alpha", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2006-05", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-11-15T12:24:05.337Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00445523" }, { "nct_id": "NCT01479868", "title": "A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus Genotype-1" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Pegylated interferon alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 109, "start_date": "2011-10", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-10-29", "last_synced_at": "2026-11-15T12:24:05.337Z", "location_count": 10, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01479868" }, { "nct_id": "NCT01252355", "title": "Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis Relapse" ], "interventions": [ { "name": "Teriflunomide", "type": "DRUG" }, { "name": "Placebo (for teriflunomide)", "type": "DRUG" }, { "name": "Interferon-beta (IFN-beta)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 534, "start_date": "2011-01", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-11-15T12:24:05.337Z", "location_count": 32, "location_summary": "Cullman, Alabama • Cordova, Alaska • Phoenix, Arizona + 26 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Cordova", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252355" }, { "nct_id": "NCT00099489", "title": "Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Inflammatory Demyelinating Polyradiculoneuropathy" ], "interventions": [ { "name": "Interferon Beta-1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 67, "start_date": "2004-02", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2010-03-05", "last_synced_at": "2026-11-15T12:24:05.337Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00099489" } ] }